Exosome-based delivery of Wedelolactone shows promise for sepsis-induced liver injury
A novel exosome-based drug delivery system (Exo@WEL) enhances liver-targeting and hepatoprotection of Wedelolactone.
Asset / Drug
Drug and asset intelligence for Wedelolactone with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.